Figure 5.

The activation of the AMPK-Erk pathway contributed to dysregulating osteogenesis by FGFR2 p.Cys342Arg: (A) Western blot analysis showed that the expression of t-AMPK and p-AMPK were upregulated in the MT group compared with the WT group and the expression of t-AMPK and p-AMPK were downregulated in the siFGFR2 group compared with the control. (B) ALP staining, alizarin red staining and quantification test demonstrated that both ALP activity and mineralization were decreased after the AMPK pathway was inhibited. (C) The expressions of osteogenic markers Alp, ColI, Runx2 and Ocn were reduced after being treated with Compound C, as determined by qRT-PCR and Western blot. (D) Western blot analysis showed that the level of p-Erk was effectively inhibited after being treated with Compound C. However, the level of p-AMPK had no significant change after the U0126 treatment. p values were significant at * p < 0.05, ** p < 0.01 and **** p < 0.0001.